MAPT and Alzheimer disease: Plasma p-tau181 can be robustly measured in plasma and is highly specific for AD pathology (Mielke et al., 2018), making it an attractive screening tool for brain Aβ and tau pathologies jointly as required for A/T/N biomarker profiling (Jack et al., 2018) linked to differential trajectories of disease progression (Altomare et al., 2019; Jack et al., 2019; Ebenau et al., 2020).